CJC-1295 and ipamorelin: what the evidence says and what the FDA says

CJC-1295 e ipamorelina: qué dice la evidencia y qué dice la FDA

They almost always show up in the same sentence. "CJC-1295 with ipamorelin." Two names glued together, as if they were one product.

And the promise attached is almost always the same: natural growth hormone. Sleep better. Recover faster. Lose fat while you sleep. Get back the body you had at thirty.

This article is not going to tell you that's a lie, and it's not going to tell you it's true. It's going to tell you exactly what was studied, in whom, how many people, what was measured — and, above all, what the FDA has written about each of these two peptides in its own words.

Then you decide, with a physician.

Educational content. Not medical advice. Results vary.

Two keys, one lock

To understand why they're sold together, you have to understand how your body releases growth hormone.

Growth hormone — GH — is made by your pituitary, a gland about the size of a pea at the base of your brain. It doesn't come out in a steady stream. It comes out in pulses, mostly at night, mostly during deep sleep.

That gland has two gatekeepers telling it when to release a pulse.

The first is GHRH, a hormone that comes down from the hypothalamus and essentially says: release. The second is ghrelin, the hormone your stomach makes when it's been empty for a while — the one that makes you hungry, and that also pushes the same pulse through a different door.

Two different locks on the same door.

CJC-1295 is a synthetic copy of GHRH. Ipamorelin is a synthetic copy of what ghrelin does. The logic of the stack is simple: turn both keys at once and the pulse should be bigger than turning either one alone.

That's a reasonable physiological hypothesis. But let's be clear from the start: there is no large human trial comparing the combination against either one alone. The logic is good. The proof isn't there yet.

CJC-1295: the albumin trick

Natural GHRH has a practical problem: it lasts almost no time at all. Minutes. Your body cuts it with an enzyme called DPP-4 almost as soon as it appears.

That works fine for a natural pulse, but it's useless as a medication. A Canadian lab set out to solve exactly that in the early 2000s.

They took the active fragment of human GHRH — the first 29 amino acids — and did two things to it. First, they swapped four amino acids so the enzyme couldn't cut it so easily. Second, and this is the clever part, they attached a chemical hook on the end.

That hook seeks out a specific site on albumin, the most abundant protein in your blood. The moment the molecule enters the body, it grabs onto albumin and travels attached to it.

Why does that matter? Because albumin lives for weeks in circulation. The attached molecule stops being a peptide that vanishes in minutes and becomes a long-distance passenger.

The work published in Endocrinology in 2005 confirmed it in rats: the version they named CJC-1295 was still present in plasma beyond 72 hours, and produced four times more GH release than the unmodified fragment.

So far, elegant chemistry. The real question is what happens in a person.

The human study that does exist

It exists, and it's good. It was published in the Journal of Clinical Endocrinology & Metabolism in 2006, and it's still the reference everyone cites — even though almost nobody has read it.

Two randomized, double-blind, placebo-controlled trials. Healthy adults aged 21 to 61. Ascending doses: first a single injection, then repeated weekly or biweekly doses.

The results, in numbers:

• After a single injection, mean GH rose 2- to 10-fold, and stayed elevated for 6 days or more.
• IGF-1 — the messenger GH activates in the liver, and the number that actually reflects cumulative effect — rose 1.5- to 3-fold, for 9 to 11 days.
• With repeated doses, IGF-1 stayed above baseline for up to 28 days.
• The estimated half-life was 5.8 to 8.1 days.
• No serious adverse reactions were reported. The authors noted it was better tolerated at 30 and 60 micrograms per kilogram.

That's real and it's published. If someone tells you there's "no human evidence at all" for CJC-1295, they're wrong.

But now read this sentence slowly, because it's the most important one in the article: that study measured hormones, not people.

It did not measure body fat. It did not measure muscle mass. It did not measure strength. It did not measure sleep, energy, mood, recovery or quality of life. It measured GH and IGF-1 in blood, plus short-term safety.

The authors themselves wrote it carefully: the data support the potential utility of CJC-1295 as a therapeutic agent. Potential. That word is doing a lot of work, and marketing erases it.

The "with DAC" and "without DAC" confusion

Here's a technical detail that almost never gets explained and that completely changes what you're talking about.

That albumin hook has a name: DAC. When you read "CJC-1295 with DAC," that's the molecule from the 2006 study — the one that lasts days.

When you read "CJC-1295 without DAC," that's something else. It's just the modified fragment, with no hook. Its correct name is mod GRF (1-29). It lasts minutes, not days.

Two different molecules with completely different profiles, sold under the same commercial name. And the human evidence you just read is for only one of the two.

If a seller offers you "CJC-1295" and cites the 2006 study, but what they're actually shipping is the version without DAC, they're citing a study of a different molecule. They may not even know it.

That's the kind of thing a physician checks and an internet store does not.

Ipamorelin: selective, but for what?

Ipamorelin has a different, and in some ways more honest, history.

It came out of Novo Nordisk, in Denmark, and was introduced to the world in 1998 in the European Journal of Endocrinology under a title that was almost a declaration: "Ipamorelin, the first selective growth hormone secretagogue."

It's worth understanding what "selective" means there, because it's still the main selling point today.

Molecules in that family — the GHRPs — had a known problem: along with releasing GH, they also raised ACTH and cortisol. In other words, they raised your stress hormone as a side effect. For something people take looking for recovery and sleep, that's exactly the opposite of what you want.

Ipamorelin, in that study, didn't do that. It released GH with potency similar to GHRP-6, but did not significantly raise ACTH or cortisol — and the authors underlined that this held even at doses more than 200 times above the effective dose.

That's a clean finding and it's the best argument this molecule has.

Now the other side: that study was done in rats and pigs. Not in people. The paper says so itself. And the authors' conclusion was cautious: ipamorelin's specificity makes it "a very interesting candidate for future clinical development."

That was 1998. The natural question is: what happened to that clinical development?

The human trial almost nobody cites

Something did happen, and the result is the part of this story marketing never mentions.

Ipamorelin did reach a phase 2 trial in people. But not for building muscle or sleeping better. It was for postoperative ileus: the stall in the intestine that sometimes follows abdominal surgery and keeps patients in the hospital longer.

It makes sense. Ghrelin moves the gut, so a ghrelin mimic might help it restart.

The trial was published in 2014 in International Journal of Colorectal Disease. Multicenter, randomized, double-blind, placebo-controlled. 117 patients undergoing bowel resection. Intravenous ipamorelin twice daily, for up to seven days.

The results:

• Median time to tolerating a solid meal: 25.3 hours with ipamorelin versus 32.6 hours with placebo.
• That difference did not reach statistical significance (p = 0.15). In plain language: it could have been chance.
• The authors concluded ipamorelin was well tolerated, but that there were no significant differences versus placebo in the key or secondary efficacy analyses.

That is the state of clinical evidence for ipamorelin in people. One trial, for a different indication, that found no benefit.

It's not a disaster. It doesn't make it dangerous. But it also isn't what an ad promising recovery and body composition implies.

What the FDA says, in its own words

Here it pays to be literal, because this is where the most confusion lives and where people exaggerate in both directions.

The FDA maintains a public page listing substances that, when nominated for pharmacy compounding, raised safety concerns. It's called Category 2. Here's what it says today.

On CJC-1295

The FDA writes that compounded drugs containing CJC-1295 "may pose risk for immunogenicity for certain routes of administration" and may have complexities "with regard to peptide-related impurities and API characterization."

Then it gets more specific: the agency "has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction." It closes with six words: "Available clinical data are limited."

An important and honest detail: CJC-1295 is no longer in the active Category 2 table. It appears in the table of substances "nominated but withdrawn." That means whoever nominated it pulled the nomination — not that the FDA said it's safe. The agency's concerns remain published, word for word, on that same page.

On ipamorelin

Ipamorelin appears in both tables. It's in the withdrawn-nominations table for the 503A pathway, and it remains in active Category 2 under the 503B interim policy, where it was added on September 29, 2023.

The FDA cites immunogenicity risk, notes that ipamorelin acetate "contains unnatural amino acids, which add to the complexity of peptide characterization," and writes that a study published in the literature "identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility."

That's a heavy sentence, and it needs reading precisely. It refers to the same kind of hospital setting we described above — patients just out of bowel surgery, given the drug intravenously, in hospital. The published trial reported it was well tolerated; the FDA, looking at the broader data, describes serious adverse events including deaths. Both readings are on the table and we're not hiding either from you.

The agency closes by saying it has not identified safety information for certain other injectable routes, and therefore "lacks sufficient information to know whether the drug would cause harm" by those routes.

That last sentence is the one most people misread. Insufficient information does not mean "it's dangerous." It also doesn't mean "it's safe." It means exactly what it says: nobody knows yet.

What that means in practice

• Neither one is FDA-approved for any indication in the United States.
• Neither one is on the 503A list of substances a compounding pharmacy may use from bulk.
• Coming off the active Category 2 table is not an approval, and it does not put them on the 503A list. Those are different things.
• What's sold online usually hides behind a "for research use only" label, which expressly does not authorize human consumption.

More growth hormone is not a better life

This is the least-discussed part and the one that should weigh most in your decision.

Suppose everything works exactly as the brochure promises: your GH goes up, your IGF-1 goes up. What does that turn into?

Two pieces of work answer that question directly, and neither has anything to do with selling peptides.

The first is a systematic review published in Annals of Internal Medicine in 2007. It pooled 31 articles and 18 study populations: healthy older adults, mean age 69, treated with actual growth hormone.

What did they find? Fat mass fell by about 2.1 kg and lean body mass rose by about 2.1 kg. Total weight, essentially unchanged. Bone density, unchanged.

But they also found this: people who received GH were significantly more likely to have soft tissue edema, joint pain, carpal tunnel syndrome and gynecomastia — and somewhat more likely to develop diabetes and impaired fasting glucose.

The authors' conclusion was one line: growth hormone cannot be recommended as an anti-aging therapy.

The second is even more direct, because it didn't use GH but a secretagogue — the same strategy as ipamorelin, in pill form. Published in 2008, also in Annals of Internal Medicine. Two years, double-blind, placebo-controlled, 65 healthy adults aged 60 to 81.

It worked exactly as expected hormonally: GH and IGF-1 rose to young-adult levels. And fat-free mass rose 1.1 kg, while the placebo group lost 0.5 kg. A real difference.

Now what didn't happen:

• Abdominal visceral fat did not go down. Neither did total fat.
• Limb fat increased more in the treated group than in placebo.
• Body weight rose 2.7 kg, versus 0.8 kg on placebo.
• Fasting glucose rose and insulin sensitivity decreased.
• Cortisol rose.
• And the sentence that sums it all up, written by the authors themselves: increased fat-free mass did not result in changes in strength or function.

Read it again. They gained muscle on the scale and gained nothing in real life.

That doesn't prove ipamorelin does the same thing — different molecule, different route, different dose. But it does show something uncomfortable and verifiable: raising growth hormone and improving your life are two separate questions, and the second one still has no answer.

What this evidence does NOT say

No honest article can end without this section. These are the things the evidence you just read does not support, no matter how often they show up in ads.

• It does not say CJC-1295 causes fat loss. The 2006 trial did not measure fat.
• It does not say ipamorelin improves sleep, recovery or mood. That was never measured in a controlled human trial.
• It does not say the combination beats either one alone. That comparison has not been done in a human trial.
• It does not say they're safe long-term. The longest human CJC-1295 trial ran 49 days.
• It does not say they're equivalent to prescription growth hormone, or "more natural" because they push your own gland. That's a different mechanism, not a moral category.
• It does not say anything about what's actually in the vial you buy online. That's a manufacturing problem, not a pharmacology problem — and reading studies doesn't solve it.

Who is this NOT for?

There are situations where this topic needs to be approached far more slowly, or set aside entirely. Not to scare you — so you know what to ask a physician.

• If you have or have had cancer. IGF-1 is a cell growth signal. This conversation doesn't happen without your oncologist.
• If you have diabetes or prediabetes. The evidence above shows worsening insulin sensitivity and rising fasting glucose.
• If you have heart disease or arrhythmias. The FDA specifically cites increased heart rate and a vasodilatory reaction for CJC-1295.
• If you're pregnant, nursing or trying to conceive. There is no data, and "no data" in pregnancy is handled as a no.
• If you're a minor or still growing. Developing hormonal axes don't get touched out of curiosity.
• If you compete in tested sport. Secretagogues and GHRH analogs are banned in competition. A positive test doesn't distinguish curiosity from cheating.
• If the vial comes from a website that doesn't answer the phone. That's not a clinical problem, it's a sourcing problem — and it's the most common one of all.

Frequently asked questions

Are CJC-1295 and ipamorelin FDA-approved?

No. Neither is approved for any indication, and neither appears on the 503A list that would let a compounding pharmacy prepare them from bulk substance. Ipamorelin also remains in Category 2 under the 503B interim policy, where it was added on September 29, 2023.

Why are they always sold together?

Because they act on two different receptors on the same gland: CJC-1295 mimics GHRH and ipamorelin mimics ghrelin. The idea is that pushing on two doors at once produces a bigger GH pulse. Reasonable hypothesis, but there is no human trial comparing the combination against either one alone.

So the CJC-1295 study does not count?

It counts, but it measures something else. It showed sustained increases in GH and IGF-1 in healthy adults for days. It did not measure fat, muscle, strength, sleep or quality of life. A lab number going up is not the same as feeling better.

Is ipamorelin the safer one because it does not raise cortisol?

That is the claim from its original 1998 study, done in rats and pigs. It's a real finding, but it's animal data. In the only published phase 2 human trial it was well tolerated and did not beat placebo on the primary endpoint. The FDA, for its part, says safety information is still missing for several routes of administration.

Will raising growth hormone make me stronger?

The available evidence says not necessarily. In a two-year trial of an oral secretagogue in older adults, fat-free mass did increase, but strength and function did not change, and insulin sensitivity got worse. And a systematic review of growth hormone in healthy older adults concluded it cannot be recommended as an anti-aging therapy.

What if I'm still interested?

Then the conversation belongs with a physician, not an internet store. Write to us and a licensed physician reviews your full case — what you're after, your history, what you've already tried — and tells you clearly what's possible today, what isn't yet, and what better-evidenced options exist for what you're actually dealing with.

If you're still interested: how we handle it

There was an easy way to write this article. Start the same way, talk about the pituitary, and end by selling you a vial. We didn't write that one.

Not because we're better than anyone. Because the day we sell you something that doesn't hold up, you stop believing us forever — and that's worth more than any sale.

But we're not going to do the opposite either, which is just as comfortable: telling you not to ask. Your curiosity isn't the problem. The problem is buying blind from a site that doesn't answer the phone, guided by a 2006 study that may not even be about the molecule they're shipping you.

So if after reading all this you're still interested, the conversation doesn't end here. It moves where it should have been from the start: a licensed physician looking at your full case.

Once you start your program, a licensed physician reviews your case — habits, stress, sleep and medical history — and orders labs only if they consider it necessary.

We also offer clinically supervised hormone health and weight management programs, and GLP-1 programs with FDA-approved medications (Wegovy®, Foundayo™, Ozempic®) from $149 per month, by telemedicine, in Spanish and English. That's there if it helps you — and if it doesn't, that's fine too.

Eligibility is determined by medical evaluation. Individual results vary and are not guaranteed.

Sources

Articles located through PubMed. Regulatory documents taken directly from the FDA.

• Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. 10.1210/jc.2005-1536
• Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. 10.1210/en.2004-1286
• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. 10.1530/eje.0.1390552
• Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. 10.1007/s00384-014-2030-8
• Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-6. 10.1124/jpet.108.149211
• Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-15. 10.7326/0003-4819-146-2-200701160-00005
• Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11. 10.7326/0003-4819-149-9-200811040-00003
• Ahnfelt-Rønne I, Nowak J, Olsen UB. Do growth hormone-releasing peptides act as ghrelin secretagogues? Endocrine. 2001;14(1):133-5. 10.1385/ENDO:14:1:133
• FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2; content current as of 04/22/2026). fda.gov
• FDA — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov
• FDA — Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act. fda.gov

Your trust is worth more than a sale.

More information →

This article is informational and is not medical advice. SCTS1 does not prescribe medication. All medical care, prescriptions and treatment plans are provided by licensed physicians through our partner platform. Eligibility is determined by a licensed provider. CJC-1295 and ipamorelin are not FDA-approved for any indication and, at the time of publication, do not appear on the 503A list of substances a compounding pharmacy may use; they are discussed here for informational and educational purposes only, and not as a recommendation for use. Any treatment decision belongs to a licensed physician evaluating your case. Individual results vary and are not guaranteed.